下一代肿瘤不可知靶点即将出现
Next-generation tumor-agnostic targets on the horizon.
肿瘤不可知药物开发将肿瘤学重新聚焦于共享的分子依赖性而非组织来源,从而能够针对跨肿瘤的罕见可操作驱动因素进行高效开发。
英文原题:Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study.
SWI/SNF复合物是一种染色质重塑复合物,由SMARCA4或SMARCB1等多种蛋白质组成。
SWI/SNF复合物是一种染色质重塑复合物,由SMARCA4或SMARCB1等多种蛋白组成。其组分的突变可导致侵袭性横纹肌样肿瘤的发生,如上皮样肉瘤、恶性横纹肌样瘤或卵巢高钙血症型小细胞癌等。这些恶性肿瘤往往影响年轻患者,且由于缺乏有效治疗,其预后较差。这些肿瘤的特征是高度浸润TILs,提示某些淋巴细胞正在识别肿瘤抗原。利用这些TILs作为治疗策略是一种值得探索的有前景的方法。在此,我们报告TILTS研究的临床方案,这是一项II期临床试验,评估针对受这些肿瘤类型影响的患者使用TILs进行个性化过继细胞治疗。临床试验注册:2023-504632-17-00 (www.clinicaltrialsregister.eu) (ClinicalTrials.gov)。[方框:见正文]。
The SWI/SNF complex is a chromatin remodeling complex comprised by several proteins such as SMARCA4 or SMARCB1. Mutations in its components can lead to the development of aggressive rhabdoid tumors such as epithelioid sarcoma, malignant rhabdoid tumor or small cell carcinoma of the ovary hypercalcemic type, among others. These malignancies tend to affect young patients and their prognosis is poor given the lack of effective treatments. Characteristically, these tumors are highly infiltrated by TILs, suggesting that some lymphocytes are recognizing tumor antigens. The use of those TILs as a therapeutic strategy is a promising approach worth exploring. Here, we report the clinical protocol of the TILTS study, a Phase II clinical trial assessing personalized adoptive cell therapy with TILs in patients affected by these tumor types. Clinical Trial Registration : 2023-504632-17-00 (www.clinicaltrialsregister.eu) (ClinicalTrials.gov). [Box: see text].
MEMBER ACCOUNT
登录成功会直接打开下一页。